Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute
The Methodist Hospital Research Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Columbia University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
Beth Israel Deaconess Medical Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Centre Antoine Lacassagne
M.D. Anderson Cancer Center
Swiss Cancer Institute
University of Nebraska
Georgetown University
Ohio State University Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Dana-Farber Cancer Institute
Children's Hospital of Philadelphia
Dana-Farber Cancer Institute
University of Alabama at Birmingham
University of Alabama at Birmingham
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University Hospital, Lille
The First Affiliated Hospital of Xiamen University
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Peter MacCallum Cancer Centre, Australia
First Affiliated Hospital of Zhejiang University
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
University of Virginia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Thomas Jefferson University